Ferring pharmaceuticals completes phase III study of degarelix in prostate cancer patients
-Ferring Pharmaceuticals announced today that it has successfully completed the pivotal phase III study for degarelix, its novel prostate cancer treatment…
Superior remission rates for once daily use of Pentasa® (mesalazine) in ulcerative colitis
-For the first time a once daily dosing regime of mesalazine (Pentasa® granules) has proven to be statistically superior to…
Ferring Pharmaceuticals Forges Worldwide Licensing Agreement for Budesonide MMX™
-Ferring Pharmaceuticals today announced that it had come to an agreement with Cosmo Pharmaceuticals SpA for…
Ferring Pharmaceuticals Announces Board Changes
-Ferring Pharmaceuticals today announced changes to the company’s Board of Directors. Effective immediately, Alexandra, Countess of Frederiksborg will become a new non-executive member of the Board…
New data demonstrates both cost and efficacy benefit of MENOPUR® compared to recombinant FSH treatment
-New data presented today at the European Society of Human Reproduction and Embryology (ESHRE) 2007 congress shows that…
Archives Press release 2007
Archives Press release 2007